Skip to main content

Catch by Gene, C&S Ink Supply Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Catch by Gene (CBYG) today announced a reagent supply agreement with C&S.

The deal, which is initially for $300,000, covers CBYG's test kit products for the identification of sexually transmitted diseases, including the early-stage identification of human papillomavirus. CBYG will initially provide C&S with 60,000 reagents a year, and said in a statement that it anticipates that amount to increase each year "with increased demand requirements in addition to other international distributors."

The Korean company develops, manufactures, and markets in vitro nucleic acid assays. Its technology uses multi-probes based on microplate chemiluminescence or colorimetry for the direct detection of infectious pathogens, such as hepatitis B, HPV, and Chlamydia trachomatis, the company said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.